Gadoxetic acid
 | |
| Systematic (IUPAC) name | |
|---|---|
| 2-[[2-[bis(2-oxido-2-oxoethyl)amino]-3-(4-ethoxyphenyl)propyl]-[2-[bis(2-oxido-2-oxoethyl)amino]ethyl]amino]acetate; gadolinium(+3) cation | |
| Clinical data | |
| AHFS/Drugs.com | International Drug Names |
| Identifiers | |
135326-11-3  | |
| V08CA10 | |
| PubChem | CID 219084 |
| UNII |
3QJA87N40S  |
| KEGG |
D08008 |
| ChEMBL |
CHEMBL1201769 |
| Chemical data | |
| Formula | C23H30GdN3O11 |
| 681.75 g/mol | |
| (what is this?) (verify) | |
Gadoxetic acid is a gadolinium-based MRI contrast agent. Its salt, gadoxetate disodium, is marketed as Primovist in Europe and Eovist in the United States by Bayer HealthCare Pharmaceuticals.[1]
References
- ↑ "Eovist - Homepage". Retrieved 2009-03-22.
| ||||||||||||||||||||||||||||||||||||||||||||||||